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Abstract
Purpose of Review The effect of cocoa consumption on blood pressure (BP) has been investigated in previous studies; however,
to date, no meta-analysis has been conducted specific to middle-aged and elderly subjects. Thus, the aim of the present study was
to evaluate the effect of cocoa consumption on indices of blood pressure, in middle-aged and elderly subjects.
Recent Findings Pubmed/Medline™, Cochrane Library™, Google Scholar™, and Scopus™ were searched until March 2019.
The quantitative Jadad scale was used as the systematic assessment of bias in the included trials. We used a random effects model
to estimate the pooledweightedmean differences (WMDs) with 95% confidence intervals (CIs).We further conducted sensitivity
analysis and stratified analysis by baseline blood pressure, follow-up duration, and mean age. Thirteen studies with 758 total
participants were included in the present meta-analysis. A significant reduction in SBP by 2.77 (95% CI − 5.28, − 0.27, P = 0.03,
I2 = 89%) and DBP by 1.47 mm/Hg (− 95% CI − 2.40, − 0.55, P = 0.001, I2 = 45%) were observed after cocoa consumption.
Stratified analyses showed BP-lowering effects of cocoa consumption in longer-term duration and hypertensive subgroups.
Summary Our meta-analysis showed a significant inverse association between cocoa consumption and SBP/DBP. However, the
analysis could not conclude any beneficial effect of cocoa consumption on blood pressure in normotensive/elevated blood
pressure subjects. Therefore, further studies are warranted to affirm the efficacy of cocoa consumption for the improvement of
blood pressure in elderly subjects.
Keywords Cocoa . Blood pressure . Middle-aged . Elderly . Meta-analysis
Introduction
High blood pressure, or hypertension, is an inarguably impor-
tant risk factor for cardiovascular disease and purported to be
attributable for nearly 50% of ischemic heart disease and over
50% of cerebrovascular events globally [1]. More than a third
of cardiovascular deaths are attributable to hypertension in
Western populations [2], in addition to 13.5% worldwide
[1]. Furthermore, the prevalence of hypertension is known to
increase concurrently with aging. In fact, the, now seminal,
Framingham study demonstrated that almost two-thirds of
males and three quarter of females will develop hypertension
by the age of 70 years [3–5].
The association between cardiovascular risk and blood
pressure levels is believed to be continuous [6], where the risk
of ischemic heart disease, stroke, and other comorbidities is
shown to be reduced, by nearly half, for every 20-mmHg
reduction in systolic blood pressure (SBP), and 10-mmHg
diastolic blood pressure (DBP), respectively [7•]. While man-
aging blood pressure is often difficult in older populations, not
only because of comorbidities but also due to vascular remod-
eling and the changes in renal and endocrine physiology [5], it
is evident that even small or modest reductions in blood pres-
sure may protect against cardiovascular events at a population
level.
Hypertension is typically treated using various pharmaco-
therapies. However, complementary medicine such as dietary
supplements and foods could be considered as an effective
treatment for various situations [8–10] including hypertension
[11, 12]. Chocolate and flavanol-rich cocoa-based products
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have attracted attention as an alternate treatment [13••, 14••,
15••, 16••]. Numerous randomized clinical trials examining
the effect of cocoa-rich products on BP have been undertaken
and have reported beneficial effects as compared with choco-
late containing no or negligible amounts of flavanols [13••,
14••, 15••, 16••]. The blood pressure-lowering properties of
cocoa have been putatively attributed to the formation of en-
dothelial nitric oxide (NO), which may facilitate vasodilation,
and subsequently reduces blood pressure. Increased NO pro-
duction may conceivably be triggered by upregulation of NO
synthase via the insulin-mediated signaling pathway [17].
Further, cocoa flavanols have been shown to inhibit angioten-
sin converting enzyme activity, and therein reduce blood pres-
sure [18, 19]. Recently, numerous clinical trials have investi-
gated the effect of chocolate and cocoa-based products on
blood pressure. Although, there are several meta-analysis
which investigated the blood pressure-lowering effect of co-
coa consumption [13••, 14••, 16••]; however, to date, no meta-
analysis has been conducted specific to middle-aged and el-
derly subjects, and given the marked benefits associated with
blood pressure reduction in this population, and the prediction
that by the year 2050, one-fifth of the world population will
surpass 80 years of age [20••], the aim of the present study was
to investigate the effect of cocoa consumption on indices of
blood pressure, in middle-aged and elderly subjects, manifest
in randomized controlled trials (RCTs).
Methods
Literature Search
The current systematic review and meta-analysis was con-
ducted according to the PRISMA guidelines [21•] and
Cochrane Handbook for Systematic Reviews [22•]. Pubmed/
Medline™, Cochrane Library™, Google Scholar™, and
Scopus™ were searched until March 2019. We comprehen-
sively searched for RCTs that investigated the efficacy of co-
coa consumption on blood pressure in middle-aged and elder-
ly subjects. Moreover, the reference lists of pertinent studies
were manually investigated to explore additional potentially
relevant studies. Both free text and MeSH items were used in
titles and abstracts as follow: (“cacao” [MeSh] OR “cocoa”
OR “chocolate”) AND (“Blood Pressure” [MeSh] OR “Blood
Pressure” OR “Hypertension” [MeSh] OR “Prehypertension”
[MeSh] OR “SBP”OR “DBP”. The searches were not restrict-
ed based on the language and the searches were limited to
human studies.
Study Selection
We selected the original studies if they met the following
inclusion criteria: (1) consumption of any cocoa products
including chocolate (as bar, powder) or drink, cocoa, or re-
fined cocoa flavan-3-ols compared with a control group, (2)
random allocation to intervention and control group, (3) stud-
ies with blood pressure measurements at the baseline and end
of the trial (reported mean changes and standard deviations or
necessary data for calculating in the case of unavailable val-
ue), (4) participants with the mean age of ≥ 45 years as the
middle-aged and ≥ 65 years as the elderly subjects. We did not
restrict the studies according to participant’s gender, clinical
condition, and baseline blood pressure. The raw data were
extracted independently by two reviewers, and discrepancies
were subsequently adjudicated by the third reviewer. We tried
to contact the authors of publications in which necessary mea-
surements were insufficient to obtain additional study data.
Data Extraction
The following data were extracted by using a standard form
and cross-checked (Table 1). The first author of the publica-
tion, year of publication, location of study, age and gender of
subjects, the sample size of intervention/control groups,
follow-up duration, intervention/control treatments and dos-
ages, clinical condition of participants, design of trials, base-
line blood pressure, and significant reported outcomes.
Quality Assessment
We used the quantitative Jadad scale as the systematic assess-
ment of bias in the included trials with the score ranges from 0
to 5. Higher scores suggest higher quality. The scale includes
three main parameters: randomization, blinding, and monitor-
ing of subject drop outs with the following scoring system:
one point for stating random allocation and one additional
point if the method of randomization was suitable. One point
was given for stating the blinding and one more point if the
method of blinding was appropriate. One point was deducted
in the case of inappropriate method of randomization or
blinding. Finally, another extra point was given for stating
the withdrawals with the reasons [23•].
Statistical Analysis
The data synthesis was conducted using Review Manager
Software (Review Manager 5.3; Cochrane Collaboration,
Oxford, England) and Comprehensive Meta-Analysis (ver-
sion 3.2; Biostat). The change and standard deviation (SD)
in SBP and DBP between intervention and control groups
were presumed as the outcomes. We estimated the SD by
[SD = SEM × sqrt (n); n = number of subjects] when standard
error of mean (SEM) was reported in the trials. In the case or
reported data as median/mean and variation range or inter-
quartile range, the method of Hozo et al. were calculated to
estimate the SDs [24•]. The statistical heterogeneity was
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quantitatively estimated using I2 statistic test and χ2 on
Cochrane’s Q statistic test. According to the observed hetero-
geneity among trials and Cochrane Handbook Guideline
[22•], random effects were used in the meta-analysis.
Pre-specified subgroup analyses were conducted by com-
paring different treatment characteristics: (i) duration of treat-
ment: shorter-term trials (treatment duration of less than
6 weeks) [25–29] vs. longer-term trials (treatment duration
≥ 6 weeks) [30–37]; (ii) mean age of participants in interven-
tion group: 9 trials with middle-aged participants (between 45
and 65 years old) [25, 27, 31, 32, 34, 37] and 6 trials with
elderly subjects (≥ 65 years old) [28, 30, 33, 35] and 3 trials
with unknown mean age in the intervention group [26, 29,
36]; (iii) baseline BP level: 3 trials with normotensive subjects
[25, 27], 5 trials with elevated blood pressure subjects
[29–32], and 10 trials with hypertensive patients [26, 28, 31,
33–37]. Different subgroups based on follow-up duration and
baseline BP level divided by their medians. Additionally, the
influence of single studies on the pooled weighted mean dif-
ference was executed by conducting sensitivity analyses ac-
cording to the Cochrane guidelines [38•].
The potential publication bias was investigated by multiple
analysis including Egger’s weighted regression test, Begg’s
rank correlation method, and funnel plots test. The asymmet-
ric shape of funnel plot is considered as a positive indicator of
a publication bias. A P value of less than 0.05 was considered
as statistically significant in the analyses.
Results
Results of the Literature Search
We initially identified a total number of 438 potentially eligi-
ble articles. Of these, 381 articles were excluded because they
were duplicated studies, were irrelevant to the purpose of the
present meta-analysis, and were excluded after title and ab-
stract assessment because they were review, editorial, and let-
ter studies. Finally, full-text screening of the 57 potentially
relevant articles resulted in 13 eligible studies [25–37]. The
main reasons for exclusion were as follows: cocoa was not
given as the primary or secondary intervention; the designs of
the studies were not randomized placebo controlled; studies
which did not report sufficient detail for being included in the
present meta-analysis and trials which did not have the appro-
priate placebo/control arm or appropriate design. Four includ-
ed studies [27, 31, 33, 35] used different arms investigated
different dosages of cocoa and/or participants with different
clinical conditions; therefore, according to Cochrane guide-
lines, all of these arms are considered as dependent trials.
Finally, 13 studies with 18 trials with 758 total participants
were included in the present meta-analysis. A flow diagram
detailing the number of records retrieved by individual
searches and the number of included trials of the present
meta-analysis is presented in Fig. 1.
Study Characteristics
The characteristics of the 18 included trials with 379 partici-
pants in the intervention group and 379 participants in control
group are shown in Table 1. Different forms of cocoa were
administered in the included trials including cocoa drink or
powder of dark chocolate. The sample size of the trials varied
from 9 to 45 participants. As for the 18 trials that evaluated
hemodynamic parameters, 4 trials investigated the effect of
cocoa on healthy adults [27, 30, 32]. The other studies inves-
tigated the beneficial effects of cocoa consumption in patients
with type 2 diabetes (n = 3) [29, 34, 36], overweight and obe-
sity (n = 1) [26], cognitive function disorders (n = 4) [33, 35],
pre-hypertension and hypertension (n = 4) [29, 31, 37], hemo-
dialysis [28], and congestive heart failure (CHF) (n = 1) [25].
All included trials were published between 2007 and 2016.
Of these, 2 trials were conducted in USA [29, 30], 4 in
Australia [31, 32], Italy [33, 35], 2 in Netherlands [27],
Germany [28, 37], and the remaining 4 trials were carried
out in Iran [34], Spain [26], Switzerland [25], and UK [36].
All of the included trials reported the types of consumed
cocoa products. Additionally, all included studies reported the
doses of functional ingredients of the cocoa products.
Different types of cocoa used in the trials varied in their func-
tional compounds including flavanols, proanthocyanidin, and
theobromine. The duration of treatment varied from 4 to
18 weeks. Seventeen of the included trials used parallel
[25–35, 37] and the remaining one trial used a crossover de-
sign [36]. The mean age of participants in intervention varied
between 45.3 ± 4.4 and 70.0 ± 0.88 years. According to the
recent American College of Cardiology/American Heart
Association (ACC/AHA) updated guidelines; 3 included trials
have been conducted in normotensive subjects [25, 27], an-
other 5 trials in participants with elevated blood pressure
[29–32], and 10 remaining trials were enrolled in the hyper-
tensive patients [26, 28, 31, 33–37] with the ranges of 109.5 to
147.7 and 65.8 to 86.4 for mean baseline SBP and DBP in the
intervention groups, respectively.
Quality Assessment
The quality of studies was assessed by using the Jadad scale.
According to the previous studies, the trials with Jadad score
of equal or more than 3 are considered as high quality.
Otherwise, they will be categorized as low-quality trials. As
detailed in Table 2, 15 trials were identified as high-quality
trials [25–30, 32–37]. Other 3 trials are categorized as low-
quality studies [31].
Of all included trials, 10 [25–28, 30, 31, 37], 12 [25, 27, 28,
30, 33–37], and 14 [25–30, 32, 33, 35–37] trials obtained full
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points of randomizations, blinding, and withdrawal domains,
respectively.
The Effects of Cocoa Product Consumption on Blood
Pressure
Of the 18 included trials, 12 with 577 participants [25, 28,
30–35, 37] and 10 with 440 participants [27, 31–35, 37] re-
vealed an inverse association between cocoa consumption
with SBP and DBP, respectively. The results from the meta-
analyses revealed a significant reduction in SBP by 2.77 (95%
CI − 5.28, − 0.27, P = 0.03, I2 = 89%, P value for heterogene-
ity < 0. 001) and DBP by 1.47 mm/Hg (− 95% CI − 2.40, −
0.55, P = 0.001, I2 = 45%, P value for heterogeneity = 0.02)
after cocoa consumption (Fig. 2). The meta-analysis was per-
formed using a random effects model and to explore the
potential source of heterogeneity, we conducted subgroup
analysis.
Subgroup Analysis
Subgroup analyses were conducted to explore the effect of
cocoa consumption on SBP and DBP, according to the differ-
ent characteristics of trials including mean age of participants
in intervention groups, follow-up duration, and baseline BP
levels of subjects (Table 3).
Subgrouping by mean age (middle age vs. elderly) showed
significant changes in both SBP and DBP. However, the anal-
ysis suggested greater and significant effects for SBP (WMD
− 5.26, 95% CI − 7.58, − 2.94, P < 0.001, I2 = 34%, P value
for heterogeneity = 0.18) and DBP (WMD − 2.01, 95% CI −
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3.35, − 0.68, P < 0.001, I2 = 0%, P value for heterogeneity =
0.46) in elderly subgroup with no significant heterogeneity.
When we stratified by follow-up duration, studies of
longer-term cocoa consumption improved both SBP by
4.00 mm/Hg (95% CI − 5.49, − 2.52, P < 0.001, I2 = 41%, P
value for heterogeneity = 0.07) and DBP by 2.04 (95% CI −
2.95, − 1.13, P < 0.001, I2 = 24%, P value for heterogeneity =
0.20), whereas the shorter-term subgroup did not indicate any
beneficial effects of cocoa consumption on SBP and DBP.
When we subgrouped studies comparing different levels of
baseline BP, no significant differences in efficacy was ob-
served in normotensive subjects and patients with elevated
blood pressure. There were differences in efficacy of cocoa
consumption on improving SBP (WMD − 4.60, 95% CI −
6.26, − 2.94, P < 0.001, I2 = 38%, P value for heterogeneity =
0.12) and DBP (WMD − 2.16, 95% CI − 2.95, − 1.38,
P < 0.001, I2 = 3%, P value for heterogeneity = 0.41) in sub-
groups of hypertensive subjects.
Sensitivity Analysis
The pooledweightedmean difference after sensitivity analysis
ranged from − 2.37 (95% CI = − 4.9, 0.17) to − 3.62 (95%
CI = − 5.01, − 2.23) in SBP and from − 1.22 (95% CI = −
2.05, − 0.38) to − 1.75 (95% CI = − 2.62, − 0.88) in DBP
(Fig. 3).
Publication Bias
The symmetric vision of funnel plots and the data of Egger
tests suggested no significant publication bias in the meta-
analyses of both SBP (Egger test: intercept, − 1.37; standard
error: 0.96; 95% CI − 3.41, 0.66; t = 1.42, df = 16; two-tailed
P = 0.17) and DBP (Egger test: intercept, − 0.33; standard
error: 0.50; 95% CI − 1.40, 0.72; t = 0.67, df = 16; two-tailed
P = 0.50) (Fig. 4).
Discussion
Our meta-analysis, including 18 trials, showed that a signifi-
cant inverse association between cocoa consumption and SBP
and DBP in middle-aged or elderly subjects. There are several
meta-analysis studies that have investigated the effect of cocoa
consumption on blood pressure [13••, 14••, 15••, 16••].
However, to our knowledge, the current study is the first anal-
ysis from trials on the efficacy of cocoa consumption on blood
pressure in middle-aged and elderly subjects.
Although the significant SBP- and DBP-lowering effects of
cocoa in the middle-aged and elderly subjects was observed, the
overall effect size was relatively small and could not be consid-
ered as clinically relevant in middle-aged participants. In con-
trast, the clinical importance of SBP- and DBP-lowering effects
of cocoa in elderly subjects must be taken into account. For
instance, it has been shown that a decline of 5 mmHg in systolic
blood pressure may decrease the risk of cardiovascular diseases
by about 20% over a period of 5 years [2]. The Framingham
Heart Study demonstrated that a reduction of 2 mmHg in DBP
was associated with a 6% reduction in the risk of CHD [3].With
respect to lifestyle changes, it has been shown that structured
exercise longer than 150 min/week was associated with reduc-
tions in SBP by about 3 mmHg and DBP by about 1.5 mmHg
[4]. Furthermore, the DASH dietary pattern, as an approach for
improving the hypertension complications, reduced SBP by
5.5 mmHg and DBP by 3 mmHg overall [5].
Previous meta-analyses showed significant reductions of
SBP and DBP after cocoa consumption [13••, 14••, 15••,
16••]. Desch et al. revealed a mean blood pressure change of
− 4.5 and − 2.5 for SBP and DBP, respectively [13••].
Table 2 Quality of the included
studies according to the Jadad
scale tool
Study; year Blinding Randomization Withdrawals and dropouts descriptions Score
Crews 2008 2 2 1 5
Davison 2008 1 1 1 3
Davison 2010 0 2 0 2
Desideri 2012 2 1 1 4
Flammer 2011 2 2 1 5
Haghighat 2013 2 1 0 3
Ibero-Baraibar 2016 1 2 1 4
Mastroiacovo 2014 2 1 1 4
Mellor 2010 2 1 1 4
Neufinger 2013 2 2 1 5
Rassaf 2015 2 2 1 5
Sorond 2013 1 1 1 3
Taubert 2007 2 2 1 5
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Similarly, Ried et al. showed a reduction of 1.76 mmHg in
both SBP and DBP after cocoa consumption [16••]. All of
previous meta-analysis emphasized on the blood pressure-
lowering effects of cocoa consumption in line with our study
which could detect a significant effect of cocoa consumption
and blood pressure in elderly or middle-aged subjects. Our
pooled mean differences and effect sizes are bigger in com-
pared with the previous studies which prove promising effects
of cocoa consumption on blood pressure indices in middle-
aged and elderly subjects. This could be because the previous
reports pooled all trials with different age ranges. In this situ-
ation, it would be possible that the trials with lower mean age
of participants show different patterns of effect sizes in blood
pressure in compared with middle-aged/elderly subjects.
Therefore, that could be the possible reason of relatively large
effect sizes of our study in compared with previous meta-
Difference in means and 95% CI
Difference Standard 
in means error Variance Z-Value p-Value
Crews 2008 systolic bp 0.530- 2.163 4.680 0.245- 0.806458
Davison  2008 systolic bp 6.100- 3.181 10.117 1.918- 0.055135
Davison (a) 2010 systolic bp 0.300- 2.688 7.223 0.112- 0.911119
Davison (b) 2010 systolic bp 0.900 2.523 6.368 0.357 0.721345
Davison (c) 2010 systolic bp 4.400- 2.458 6.043 1.790- 0.073468
Desideri (a) 2012 systolic bp 8.700- 2.519 6.347 3.453- 0.000554
Desideri (b) 2012 systolic bp 6.800- 2.475 6.128 2.747- 0.006014
Flammer 2011 systolic bp 7.400- 7.099 50.399 1.042- 0.297240
Haghighat 2013 systolic bp 5.300- 1.841 3.388 2.879- 0.003985
Ibero-Baraibar 2016 systolic bp 2.000 2.843 8.084 0.703 0.481779
Mastroiacovo (a) 2014 systolic bp 5.200- 1.827 3.339 2.846- 0.004433
Mastroiacovo (b) 2014 systolic bp 6.200- 1.770 3.133 3.503- 0.000460
Mellor 2010 systolic bp 0.000 7.482 55.975 0.000 1.000000
Neufinger (a) 2013 systolic bp 0.000 7.490 56.107 0.000 1.000000
Neufinger (b) 2013 systolic bp 3.600 7.589 57.590 0.474 0.635226
Rassaf 2015 systolic bp 2.000- 6.816 46.452 0.293- 0.769181
Sorond 2013 systolic bp 3.900 0.482 0.233 8.084 0.000000
Taubert 2007 systolic bp 3.000- 0.482 0.233 6.219- 0.000000
2.776- 1.279 1.635 2.172- 0.029891
-20.00 -10.00 0.00 10.00 20.00
Favours intervention Favours control
Study name Outcome Statistics for each study Difference in means and 95% CI
Difference Standard 
in means error Variance Z-Value p-Value
Crews 2008 diastolic bp 0.070 1.411 1.990 0.050 0.960423
Davison  2008 diastolic bp 4.600- 2.256 5.088 2.039- 0.041427
Davison (a) 2010 diastolic bp 0.500- 1.526 2.328 0.328- 0.743162
Davison (b) 2010 diastolic bp 0.200 1.320 1.742 0.152 0.879550
Davison (c) 2010 diastolic bp 2.700- 1.423 2.026 1.897- 0.057838
Desideri (a) 2012 diastolic bp 3.900- 1.587 2.518 2.458- 0.013978
Desideri (b) 2012 diastolic bp 2.500- 1.791 3.208 1.396- 0.162781
Flammer 2011 diastolic bp 0.500 4.410 19.446 0.113 0.909726
Haghighat 2013 diastolic bp 6.000- 1.838 3.378 3.264- 0.001097
Ibero-Baraibar 2016 diastolic bp 1.890 1.807 3.265 1.046 0.295557
Mastroiacovo (a) 2014 diastolic bp 1.600- 1.598 2.554 1.001- 0.316774
Mastroiacovo (b) 2014 diastolic bp 3.100- 1.488 2.215 2.083- 0.037265
Mellor 2010 diastolic bp 0.000 3.999 15.988 0.000 1.000000
Neufinger (a) 2013 diastolic bp 0.300- 5.684 32.309 -0.053 0.957908
Neufinger (b) 2013 diastolic bp 0.900 5.512 30.378 0.163 0.870288
Rassaf 2015 diastolic bp 0.000 3.259 10.623 0.000 1.000000
Sorond 2013 diastolic bp 0.000 0.439 0.193 0.000 1.000000
Taubert 2007 diastolic bp 1.900- 0.439 0.193 4.328- 0.000015
1.479- 0.470 0.221 3.147- 0.001650
-20.00 -10.00 0.00 10.00 20.00
Favours intervention Favours control
a 
b 
Study name Outcome Statistics for each study
Fig. 2 Forest plot of mean differences in a systolic blood pressure (mmHg) and b diastolic blood pressure (mmHg) by using a random effects model
Page 9 of 15 1Curr Hypertens Rep (2020) 22: 1
analysis, as they analysed all trials disregard to mean age of
subjects. On the other hand, subgrouping the subjects accord-
ing to their mean ages could lead to more homogenous results
with more specific effect sizes.
Our study showed a reduction of 2.77 mmHg in SBP and
1.47 mmHg in DBP after cocoa consumption in middle-aged
and elderly subjects. Nevertheless, due to the observed signif-
icant heterogeneity explored between the included trials in
SBP and DBP analyses and the potential influence of the
heterogeneity on the accuracy of the final results, we tried to
conduct a stratified analysis on the basis of stated moderators
to find the possible source of heterogeneity.
The stratified analyses revealed that cocoa consumption in
middle-aged groups significantly decreased both SBP and
DBP. Moreover, we could confirm the SBP- and DBP-
lowering effect of cocoa consumption on elderly subjects with
a low heterogeneity among trials which make the findings
more reliable. The observed effect size in elderly subjects
(SBP − 5.26 mmHg and DBP − 2.01 mmHg) was consider-
able and comparable with the effects of other lifestyle modi-
fications on blood pressure. Additionally, it was evident that
longer-term consumption of cocoa improved both SBP and
DBP, whereas the shorter-term consumption did not show
any beneficial effects on either SBP or DBP. Interestingly,
the mean changes in longer-term cocoa consumption (SBP
− 4.00 mmHg and DBP −2.04) were comparable with clini-
cally relevant values. Moreover, unlike the normotensive and
elevated blood pressure subjects, there were beneficial effects
of cocoa consumption on SBP and DBP in subgroups
consisting of those who had existing hypertensive.
Some previous studies [13••] suggested that the mean dif-
ferences in outcome is not dependent on baseline blood pres-
sure, which is in contrast with the present meta-analysis,
whereas another meta-analysis study revealed that flavanol-
rich cocoa products did not reduce the blood pressure signif-
icantly in the normotensive subgroups [15••]. Moreover, in a
recent meta-analysis, Ried et al. showed that baseline blood
pressure may have a potential role in the efficacy of cocoa
consumption on improving blood pressure, which is in agree-
ment with the present meta-analysis [16••].
The observed heterogeneity was reduced statistically in the
normotensive and hypertensive subjects, suggesting that the
effect size based on the subgroup analysis is highly compara-
ble and can be interpreted with relative confidence. However,
heterogeneity did not reduce in the elevated blood pressure
subgroups, which may be influenced by varying, pre-
existing conditions of patients, and administered drugs.
These results are in agreement with studies investigating the
effect of various supplements on hemodynamic parameters,
which similarly showed that blood pressure is dependent on
baseline blood pressure, and hypertensive subgroups revealed
diminished effects on blood pressure, as compared with nor-
motensive subjects [39, 40].
Contrary to our study, the meta-regression analysis per-
formed by Ried et al. did not suggest any association between
duration of cocoa consumption and blood pressure outcomes
[15••], while the subgroup analysis in our study demonstrated
both SBP- and DBP-lowering effects of longer-term (≥
6 weeks) cocoa consumption in middle-aged and elderly
subjects.
Table 3 Stratified analysis
examining the effect of cocoa
consumption on systolic and
diastolic blood pressure compared
with controls
Subgroup WMD (95% CI) Test for overall
effect
Test for
heterogeneity
I2
(%)
Stage
Normal SBP − 1.52 (− 9.86, 6.83) P = 0.72 P = 0.55 0
DBP 0.40 (− 5.36, 6.16) P = 0.89 P = 0.99 0
Elevated SBP − 0.77 (− 4.89, 3.35) P = 0.71 P < 0.001 81
DBP − 0.78 (− 2.17, 0.62) P = 0.28 P = 0.13 44
Hypertension SBP − 4.60 (− 6.26, − 2.94) P < 0.001 P = 0.12 38
DBP − 2.16 (− 2.95, − 1.38) P < 0.001 P = 0.41 3
Follow-up duration, weeks
< 6 SBP 3.75 (2.83, 4.68) P < 0.001 P = 0.56 0
DBP 0.11 (− 0.71, 0.93) P = 0.79 P = 0.96 0
≥ 6 SBP − 4.00 (− 5.49, − 2.52) P < 0.001 P = 0.07 41
DBP − 2.04 (− 2.95, − 1.13) P < 0.001 P = 0.20 24
Age
Middle-aged SBP − 3.02 (− 3.88, − 2.16) P < 0.001 P = 0.48 0
DBP − 1.95 (− 3.15, − 0.75) P = 0.001 P = 0.22 25
Elderly SBP − 5.26 (− 7.58, − 2.94) P < 0.001 P = 0.18 34
DBP − 2.01 (− 3.35, − 0.68) P < 0.001 P = 0.46 0
SBP, systolic blood pressure; DBP, diastolic blood pressure
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In a recent meta-analysis study [16••], the authors conclud-
ed that the age of subjects may have a decisive role in the
effect of cocoa on blood pressure, with younger subjects
responding with greater, and indeed significant, reductions
of blood pressure; notwithstanding, this needs to be further
investigated in order to establish a plausible mechanism
[16••]. Thus, it is pragmatic to respect that the age of partici-
pants may conceivably result in varying responses in blood
pressure, following cocoa consumption. There are hemody-
namic mechanisms which can justify the age-related hyper-
tension and the effect of intervention on hypertension. In a
recent study, it was shown that an increased DBP is a strong
risk factor for developing hypertension in younger subjects (<
50 years), while in the older subjects (≥ 50 years), increased
SBP was purportedly the predominant risk factor [41]. The
mechanisms underlying the explanation of the differences be-
tween younger and older patient responses with respect of BP
elevation are equivocal. However, a putative reason is the
close association between elevation of DBP and increased
vascular resistance, which decreases with age due to sympa-
thetic nervous activation [41]. Increased vascular stiffness de-
velops an elevated BP in elderly subjects, which is mainly due
to an increase in stiffness of the large arteries. This results in a
considerable augmentation of central SBP in late systole and
Study name Outcome Statistics with study removed Difference in means (95% CI) with study removed
Standard Lower Upper 
Point error Variance limit limit Z-Value p-Value
Crews 2008 systolic bp-2.940 1.347 1.816 -5.581 -0.299 -2.1820.029138
Davison  2008 systolic bp-2.581 1.317 1.734 -5.161 0.000 -1.9600.050034
Davison (a) 2010 systolic bp-2.939 1.336 1.785 -5.557 -0.320 -2.2000.027823
Davison (b) 2010 systolic bp-3.026 1.338 1.791 -5.649 -0.404 -2.2620.023723
Davison (c) 2010 systolic bp-2.664 1.331 1.772 -5.273 -0.055 -2.0010.045362
Desideri (a) 2012 systolic bp-2.373 1.300 1.690 -4.921 0.175 -1.8260.067897
Desideri (b) 2012 systolic bp-2.500 1.316 1.732 -5.079 0.080 -1.8990.057530
Flammer 2011 systolic bp-2.665 1.296 1.679 -5.205 -0.125 -2.0570.039705
Haghighat 2013 systolic bp-2.580 1.332 1.774 -5.191 0.030 -1.9370.052737
Ibero-Baraibar 2016systolic bp-3.080 1.331 1.771 -5.688 -0.472 -2.3150.020628
Mastroiacovo (a) 2014systolic bp-2.588 1.333 1.777 -5.201 0.025 -1.9410.052278
Mastroiacovo (b) 2014systolic bp-2.507 1.321 1.745 -5.096 0.082 -1.8980.057755
Mellor 2010 systolic bp-2.838 1.298 1.684 -5.382 -0.295 -2.1870.028736
Neufinger (a) 2013 systolic bp-2.838 1.298 1.684 -5.382 -0.295 -2.1870.028739
Neufinger (b) 2013 systolic bp-2.915 1.296 1.681 -5.456 -0.375 -2.2490.024520
Rassaf 2015 systolic bp-2.796 1.300 1.690 -5.344 -0.248 -2.1510.031483
Sorond 2013 systolic bp-3.623 0.709 0.502 -5.012 -2.234 -5.1120.000000
Taubert 2007 systolic bp-2.746 1.511 2.282 -5.707 0.215 -1.8180.069111
-2.776 1.279 1.635 -5.282 -0.271 -2.1720.029891
-8.00 -4.00 0.00 4.00 8.00
Favours intervention Favours control
Study name Outcome Statistics with study removed Difference in means (95% CI) with study removed
Standard Lower Upper 
Point error Variance limit limit Z-Value p-Value
Crews 2008 diastolic bp-1.601 0.495 0.245 -2.571 -0.630 -3.2310.001232
Davison  2008 diastolic bp-1.361 0.469 0.220 -2.280 -0.441 -2.9000.003734
Davison (a) 2010 diastolic bp-1.555 0.498 0.248 -2.530 -0.579 -3.1230.001791
Davison (b) 2010 diastolic bp-1.619 0.495 0.245 -2.589 -0.649 -3.2720.001069
Davison (c) 2010 diastolic bp-1.394 0.492 0.242 -2.358 -0.430 -2.8350.004584
Desideri (a) 2012 diastolic bp-1.319 0.471 0.222 -2.242 -0.395 -2.7980.005139
Desideri (b) 2012 diastolic bp-1.431 0.490 0.240 -2.392 -0.471 -2.9210.003493
Flammer 2011 diastolic bp-1.507 0.480 0.230 -2.448 -0.566 -3.1390.001695
Haghighat 2013 diastolic bp-1.222 0.425 0.181 -2.055 -0.389 -2.8750.004047
Ibero-Baraibar 2016diastolic bp-1.636 0.468 0.219 -2.554 -0.718 -3.4930.000477
Mastroiacovo (a) 2014diastolic bp-1.482 0.497 0.247 -2.457 -0.507 -2.9790.002893
Mastroiacovo (b) 2014diastolic bp-1.368 0.485 0.236 -2.319 -0.416 -2.8180.004835
Mellor 2010 diastolic bp-1.505 0.481 0.232 -2.449 -0.562 -3.1280.001760
Neufinger (a) 2013 diastolic bp-1.494 0.480 0.230 -2.434 -0.553 -3.1130.001851
Neufinger (b) 2013 diastolic bp-1.502 0.479 0.229 -2.441 -0.563 -3.1360.001712
Rassaf 2015 diastolic bp-1.514 0.483 0.233 -2.461 -0.568 -3.1370.001706
Sorond 2013 diastolic bp-1.757 0.444 0.197 -2.627 -0.887 -3.9590.000075
Taubert 2007 diastolic bp-1.435 0.538 0.290 -2.490 -0.380 -2.6660.007685
-1.479 0.470 0.221 -2.400 -0.558 -3.1470.001650
-4.00 -2.00 0.00 2.00 4.00
Favours intervention Favours control
a
b
Fig. 3 Sensitivity analysis for a systolic blood pressure and b diastolic blood pressure
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cardiac afterload [41] and is considered a putative mechanism
that explains the increase in SBP and decrease in DBP in an
aged population [42]. Additionally, recent studies have shown
that elevated SBP variability was related to age and is depen-
dent upon vascular stiffness [43, 44], whereas DBP variability
did not show any interaction with age [45, 46].
In general, it has been shown that pulse pressure increases
significantly after the age of 50 years which could be as a result
of arterial wall stiffening leads to associated increment in SBP
and fall in DBP [47]. The findings derived from the Framingham
Heart Study, demonstrated a continuous increase of SBP be-
tween the ages of 30 and 84 years, whereas DBP showed a
varying pattern of increasing until the fifth decade and decreas-
ing from the sixth decade to at least 84 years of age [48].
Whereas both SBP and DBP are independently considered
as important predictors of CVD in younger people, SBP
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Fig. 4 Funnel plot of meta-analysis of a systolic blood pressure and b diastolic blood pressure
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should be considered as the selected predictor for elderly sub-
jects, especially those with more than 50 years of age.
Additionally, according to previous studies [49, 50], the
DBP was reduced to < 90 mmHg in 90% of subjects, whereas
the SBP was reduced to < 140 mmHg in just 60% of elderly
subjects. Therefore, it seems that DBP is more responsible to
anti-hypertensive agents in compared with the SBP in elderly
persons.
As it has been shown in the present meta-analysis, cocoa
consumption influenced the SBP and DBP regarding either
the overall results or the subgroups (except for shorter-term
consumption of cocoa and normotensive/elevated blood pres-
sure subjects). Therefore, it can be assumed that the anti-
hypertensive effect of cocoa products in middle-aged subjects
and elderly is likely limited to hypertensive subjects.
Strengths and Limitations
While there are previous meta-analytical reports explicating
that cocoa consumption can significantly lower blood pres-
sure, the current meta-analysis was first to investigate the ef-
fect of cocoa consumption in middle-aged or elderly subjects.
The observed heterogeneity decreased in a number of sub-
groups, such as normotensive and hypertensive subjects,
thereby enabling us to assert our findings as a firm evidence
that cocoa consumption may have elicit beneficial effects on
blood pressure in middle-aged or elderly subjects with hyper-
tension. Another strength of the present meta-analysis is that
wewere able to analyse a large number of trials. Moreover, the
sample sizes included in the present meta-analysis were ade-
quate. Further, we endeavoured to focus on a specific popula-
tion in an effort to ameliorate heterogeneity between studies.
Notwithstanding, the current study has several limitations,
which must be addressed. The intervention used in the studies
included a wide spectrum of treatments with different forms of
cocoa, various polyphenol content, and different dietary in-
takes which means dietary intakes of flavanol across all in-
cluding subjects was incongruent. A further limitation of the
present study was the variation of daily calorie consumption
and dietary macronutrients which may potentially influence
the metabolic response.
The lack of an adequate control arm in such trials using the
dark chocolate is considered as another limitation of the study.
One more important limitation of the present study is related
to placebo interventions: there are multiple placebo interven-
tions in the study including white chocolate and poor or low
content polyphenol chocolates or drinks. However, the lack of
beneficial health effects of consumption of white chocolate
may justify the considering of white chocolate as placebo.
One more limitation of the study is the observed statistical
heterogeneity among the trials found in the meta-analysis even
after conducting subgroup analyses with 14 comparisons,
which seems to reflect the different clinical conditions of
participants which may result in different patterns of drugs
and supplement use. Thus, the authors strongly recommend
that high-quality, randomized controlled trials, with placebo,
control, and intervention arms must be conducted, so that
veracity may be asserted in the findings of this, and indeed
all previous analyses.
Conclusion
Our meta-analysis showed a significant inverse association
between cocoa consumption and SBP/DBP. However, the
analysis could not conclude any beneficial effect of cocoa
consumption on SBP/DBP in normotensive or middle-aged
subjects. Moreover, consumption of cocoa in durations of
more than 6 weeks improved both SBP and DBP. Our work
elucidated promising effects of cocoa consumption on im-
proving blood pressure in hypertensive subjects compared
with other subjects. However, further studies are warranted
to affirm the efficacy of cocoa consumption for the improve-
ment of blood pressure in elderly subjects. Additionally, more
large-scale and high-quality studies are needed to verify the
beneficial effects of longer-term consumption of cocoa on
blood pressure.
Acknowledgments We are grateful to our colleagues for their patience
and their advice on searching the papers.
Compliance with Ethical Standards
Conflict of Interest The authors declare that they have no conflict of
interest.
Human and Animal Rights and Informed Consent This present article
does not contain any studies with human/ animal subjects conducted by
any of the authors.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-
pressure-related disease, 2001. Lancet. 2008;371(9623):1513–8.
2. Martiniuk AL, Lee CM, Lawes CM, Ueshima H, Suh I, Lam TH,
et al. Hypertension: its prevalence and population-attributable frac-
tion for mortality from cardiovascular disease in the Asia-Pacific
region. J Hypertens. 2007;25(1):73–9.
3. Kelly R, Hayward C, Avolio A, O'Rourke M. Noninvasive deter-
mination of age-related changes in the human arterial pulse.
Circulation. 1989;80(6):1652–9.
4. Seals DR, Esler MD. Human ageing and the sympathoadrenal sys-
tem. J Physiol. 2000;528(3):407–17.
Page 13 of 15 1Curr Hypertens Rep (2020) 22: 1
5. Volpe M, et al. Hypertension in the elderly: which are the blood
pressure threshold values? Eur Heart J Suppl. 2019;21(Suppl B):
B105.
6. McInnes GT. Lowering blood pressure for cardiovascular risk re-
duction. J Hypertens Suppl. 2005;23(1):S3–8.
7.• Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective
Studies Collaboration. Age-specific relevance of usual blood pres-
sure to vascular mortality: a meta-analysis of individual data for one
million adults in 61 prospective studies. Lancet. 2002;360(9349):
1903–13. References which were used mostly for their method-
ological approaches.
8. Kraft K. Complementary/alternative medicine in the context of pre-
vention of disease and maintenance of health. Prev Med.
2009;49(2–3):88–92.
9. Shen Y, et al. Fish red blood cells express immune genes and re-
sponses. Aquacult Fish. 2018;3(1):14–21.
10. Wang J, et al. Cloning and expression analysis of the nuclear factor
erythroid 2-related factor 2 (Nrf2) gene of grass carp
(Ctenopharyngodon idellus) and the dietary effect of Eucommia
ulmoides on gene expression. Aquacult Fish. 2018;3(5):196–203.
11. Nahas R. Complementary and alternative medicine approaches to
blood pressure reduction: an evidence-based review. Can Fam
Physician. 2008;54(11):1529–33.
12. Ibrahim IR, Hassali MA, Saleem F, al Tukmagi HF. A qualitative
insight on complementary and alternative medicines used by hyper-
tensive patients. J Pharm Bioallied Sci. 2016;8(4):284–8.
13.•• Desch S, Schmidt J, Kobler D, Sonnabend M, Eitel I, Sareban M,
et al. Effect of cocoa products on blood pressure: systematic review
and meta-analysis. Am J Hypertens. 2010;23(1):97–103.
Comprehensive reviews and studies which were used mostly
for their association between cocoa consumption and blood
pressure.
14.•• Taubert D, Roesen R, Schömig E. Effect of cocoa and tea intake on
blood pressure: a meta-analysis. Arch Intern Med. 2007;167(7):
626–34. Comprehensive reviews and studies which were used
mostly for their association between cocoa consumption and
blood pressure.
15.•• Ried K, et al. Does chocolate reduce blood pressure? A meta-anal-
ysis. BMCMed. 2010;8(1):39.Comprehensive reviews and stud-
ies which were used mostly for their association between cocoa
consumption and blood pressure.
16.•• Ried K, Fakler P, Stocks NP. Effect of cocoa on blood pressure.
Cochrane Database Syst Rev. 2017;4(4) :CD008893.
Comprehensive reviews and studies which were used mostly
for their association between cocoa consumption and blood
pressure.
17. Addison S, Stas S, Hayden MR, Sowers JR. Insulin resistance and
blood pressure. Curr Hypertens Rep. 2008;10(4):319–25.
18. Actis-Goretta L, Ottaviani JI, Fraga CG. Inhibition of angiotensin
converting enzyme activity by flavanol-rich foods. J Agric Food
Chem. 2006;54(1):229–34.
19. Persson IA, Persson K, Hägg S, Andersson RG. Effects of cocoa
extract and dark chocolate on angiotensin-converting enzyme and
nitric oxide in human endothelial cells and healthy volunteers–a
nutrigenomics perspective. J Cardiovasc Pharmacol. 2011;57(1):
44–50.
20.•• Aronow WS, et al. ACCF/AHA 2011 expert consensus document
on hypertension in the elderly: a report of the American College of
Cardiology Foundation Task Force on Clinical Expert Consensus
documents developed in collaboration with the American Academy
of Neurology, American Geriatrics Society, American Society for
Preventive Cardiology, American Society of Hypertension,
American Society of Nephrology, Association of Black
Cardiologists, and European Society of Hypertension. J Am Coll
Cardiol. 2011;57(20):2037–114. Comprehensive reviews and
studies which were used mostly for their association between
cocoa consumption and blood pressure.
21.• Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group.
Preferred reporting items for systematic reviews andmeta-analyses:
the PRISMA statement. Ann Intern Med. 2009;151(4):264–9 w64.
References which were used mostly for their methodological
approaches.
22.• Higgins, J.P. and S. Green, Cochrane handbook for systematic re-
views of interventions. 2008.References which were used mostly
for their methodological approaches.
23.• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ,
Gavaghan DJ, et al. Assessing the quality of reports of randomized
clinical trials: is blinding necessary? Control Clin Trials.
1996;17(1):1–12. References which were used mostly for their
methodological approaches.
24.• Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance
from the median, range, and the size of a sample. BMC Med Res
Methodol. 2005;5(1):13. References which were used mostly for
their methodological approaches.
25. Flammer AJ, Sudano I, Wolfrum M, Thomas R, Enseleit F, Périat
D, et al. Cardiovascular effects of flavanol-rich chocolate in patients
with heart failure. Eur Heart J. 2011;33(17):2172–80.
26. Ibero-Baraibar I, Romo-Hualde A, Gonzalez-Navarro CJ, Zulet
MA, Martinez JA. The urinary metabolomic profile following the
intake of meals supplemented with a cocoa extract in middle-aged
obese subjects. Food Funct. 2016;7(4):1924–31.
27. Neufingerl N, Zebregs YE, Schuring EA, Trautwein EA. Effect of
cocoa and theobromine consumption on serum HDL-cholesterol
concentrations: a randomized controlled trial. Am J Clin Nutr.
2013;97(6):1201–9.
28. Rassaf T, et al. Vasculoprotective effects of dietary cocoa flavanols
in patients on hemodialysis: a double-blind, randomized, placebo-
controlled trial. Clin J Am Soc Nephrol. 2016;11(1):108–18.
29. Sorond FA, Hurwitz S, Salat DH, Greve DN, Fisher ND.
Neurovascular coupling, cerebral white matter integrity, and re-
sponse to cocoa in older people. Neurology. 2013;81(10):904–9.
30. Crews WD Jr, Harrison DW, Wright JW. A double-blind, placebo-
controlled, randomized trial of the effects of dark chocolate and
cocoa on variables associated with neuropsychological functioning
and cardiovascular health: clinical findings from a sample of
healthy, cognitively intact older adults. Am J Clin Nutr.
2008;87(4):872–80.
31. Davison K, et al. Dose-related effects of flavanol-rich cocoa on
blood pressure. J Hum Hypertens. 2010;24(9):568.
32. Davison K, Coates AM, Buckley JD, Howe PR. Effect of cocoa
flavanols and exercise on cardiometabolic risk factors in overweight
and obese subjects. Int J Obes. 2008;32(8):1289–96.
33. Desideri G, et al. Benefits in cognitive function, blood pressure, and
insulin resistance through cocoa flavanol consumption in elderly
subjects with mild cognitive impairment: the cocoa, cognition,
and aging (CoCoA) study. Hypertension. 2012;60(3):794–801.
34. Haghighat N, et al. The effects of dark chocolate on glycemic con-
trol and blood pressure in hypertensive diabetic patients: a random-
ized clinical trial. Razi J Med Sci. 2013;20(113):78–86.
35. Mastroiacovo D, Kwik-Uribe C, Grassi D, Necozione S, Raffaele
A, Pistacchio L, et al. Cocoa flavanol consumption improves cog-
nitive function, blood pressure control, and metabolic profile in
elderly subjects: the Cocoa, Cognition, and Aging (CoCoA)
Study—a randomized controlled trial. Am J Clin Nutr.
2014;101(3):538–48.
36. Mellor DD, Sathyapalan T, Kilpatrick ES, Beckett S, Atkin SL.
High-cocoa polyphenol-rich chocolate improves HDL cholesterol
in type 2 diabetes patients. Diabet Med. 2010;27(11):1318–21.
37. Taubert D, Roesen R, Lehmann C, Jung N, Schömig E. Effects of
low habitual cocoa intake on blood pressure and bioactive nitric
oxide: a randomized controlled trial. JAMA. 2007;298(1):49–60.
Page 14 of 151 Curr Hypertens Rep (2020) 22: 1
38.• Gopalakrishnan S, Ganeshkumar P. Systematic reviews and meta-
analysis: understanding the best evidence in primary healthcare. J
Fam Med Prim Care. 2013;2(1):9–14. References which were
used mostly for their methodological approaches.
39. Kapil V, Milsom AB, Okorie M, Maleki-Toyserkani S, Akram F,
Rehman F, et al. Inorganic nitrate supplementation lowers blood
pressure in humans: role for nitrite-derived NO. Hypertension.
2010;56(2):274–81.
40. Ried K, Frank OR, Stocks NP. Aged garlic extract lowers blood
pressure in patients with treated but uncontrolled hypertension: a
randomised controlled trial. Maturitas. 2010;67(2):144–50.
41. Kanegae H, Oikawa T, Okawara Y, Hoshide S, Kario K. Which
blood pressure measurement, systolic or diastolic, better predicts
future hypertension in normotensive young adults? J Clin
Hypertens. 2017;19(6):603–10.
42. Franklin SS. Hypertension in older people: part 1. J Clin Hypertens.
2006;8(6):444–9.
43. Kario K. Prognosis in relation to blood pressure variability: pro side
of the argument. Hypertension. 2015;65(6):1163–9.
44. Kario K. Evidence and perspectives on the 24-hour management of
hypertension: hemodynamic biomarker-initiated ‘anticipation med-
icine’ for zero cardiovascular event. Prog Cardiovasc Dis.
2016;59(3):262–81.
45. Chowdhury EK, Owen A, Krum H, Wing LM, Nelson MR, Reid
CM, et al. Systolic blood pressure variability is an important
predictor of cardiovascular outcomes in elderly hypertensive pa-
tients. J Hypertens. 2014;32(3):525–33.
46. Leoncini G, Viazzi F, Storace G, Deferrari G, Pontremoli R. Blood
pressure variability and multiple organ damage in primary hyper-
tension. J Hum Hypertens. 2013;27(11):663–70.
47. Potter JF. CHAPTER 43 - Hypertension, in Brocklehurst's
Textbook of geriatric medicine and gerontology. In: Fillit HM,
Rockwood K, Woodhouse K, editors. . 7th ed. Philadelphia: W.B.
Saunders; 2010. p. 300–11.
48. Franklin SS. Ageing and hypertension: the assessment of blood
pressure indices in predicting coronary heart disease. J Hypertens
Suppl. 1999;17(5):S29–36.
49. Einhorn PT, Davis BR, Massie BM, Cushman WC, Piller LB,
Simpson LM, et al. The antihypertensive and lipid lowering treat-
ment to prevent heart attack trial (ALLHAT) heart failure validation
study: diagnosis and prognosis. Am Heart J. 2007;153(1):42–53.
50. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White
WB, et al. Principal results of the controlled onset verapamil inves-
tigation of cardiovascular end points (CONVINCE) trial. JAMA.
2003;289(16):2073–82.
Publisher’s Note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Page 15 of 15 1Curr Hypertens Rep (2020) 22: 1
